Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

This publication has 18 references indexed in Scilit:

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
  JAMA, 2016
• Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
• Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
  BMC Medicine, 2016
• Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
• Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results
  The Journal of Infectious Diseases, 2011
• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
  AIDS, 2011
• A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV Submissions
  Drug Information Journal, 2011
• Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
  European Journal of Preventive Cardiology, 2010
• Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
  The Journal of Infectious Diseases, 2010
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
  The Lancet, 2008